Janssen's Guselkumab Trial Targets Skin of Color Patients with Psoriasis
A clinical trial is underway to assess the efficacy of guselkumab in skin of color participants with moderate-to-severe psoriasis.
Therapeutic Area
Therapeutic area intelligence for Psoriasis with 2 indexed intelligence signals across regulatory, clinical, competitive, and market developments.
No catalysts indexed for this entity yet.
Newsletter
Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.
No paywall. No spam. Unsubscribe anytime.